Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

Study Identifier
M04-690
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Scientific Result Summary
Available Language(s): English

Study Details

Medical Condition
  • Crohn's Disease (CD)
  • Study Drug
  • Adalimumab
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18 - 75 Years

    Protocol Summary

    To evaluate the long-term maintenance of response, safety and tolerability of repeated

    administration of adalimumab in subjects with Crohn's disease who participated in and

    successfully completed Protocol M02-404 or Protocol M04-691.

    Study Locations

    Location
    Status
    Location
    Site Ref # / Investigator 1894
    Huntsville, Alabama, United States, 35801
    Status
    Not applicable
    Location
    Site Ref # / Investigator 1895
    Jacksonville, Alabama, United States, 35801
    Status
    Not applicable
    Location
    Site Ref # / Investigator 1787
    La Jolla, California, United States, 92037
    Status
    Not applicable
    Location
    Site Ref # / Investigator 1902
    Roseville, California, United States, 95661
    Status
    Not applicable
    Location
    Site Ref # / Investigator 1824
    San Diego, California, United States, 92123
    Status
    Not applicable
    Location
    Site Ref # / Investigator 1891
    San Diego, California, United States, 92123
    Status
    Not applicable
    Showing {first} - {last} of {total} Results